Biologic therapy for atopic asthma and beyond

Current Opinion in Allergy and Clinical Immunology

Volumn 13, Issue 6, 2013, Pages 677-685

  Caruso, Massimo ^a   Crisafulli, Emanuele ^a   Lizzio, Raffaella ^a   Polosa, Riccardo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Allergic pathway; Asthma; Biologics; MAbs

Indexed keywords

ALTRAKINCEPT; AMG 317; ANRUKINZUMAB; BENRALIZUMAB; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL PRODUCT; CORTICOSTEROID; DACLIZUMAB; DUPILUMAB; IMA 026; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; KELIXIMAB; LEBRIKIZUMAB; MEPOLIZUMAB; OMALIZUMAB; OXELUMAB; PASCOLIZUMAB; PITRAKINRA; PLACEBO; QAX 576; QGE 031; QUILIZUMAB; RESLIZUMAB; TRALOKINUMAB; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ANAPHYLAXIS; BIOLOGICAL THERAPY; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; DISEASE CONTROL; DISEASE SEVERITY; DRUG DEVELOPMENT; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHILIA; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; INFLAMMATION; LUNG FUNCTION; NAUSEA; NOSE OBSTRUCTION; PATIENT CARE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETICULOENDOTHELIAL SYSTEM; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TH2 CELL; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VIRUS MENINGITIS;

ASTHMA; BIOLOGICAL THERAPY; CLINICAL TRIALS AS TOPIC; HUMANS; MEDLINE; TH2 CELLS;

EID: 84889883288     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000012     Document Type: Review

References (70)

1. Bosnjak B, Stelzmueller B, Erb KJ, et al. Treatment of allergic asthma: modulation of Th2 cells and their responses. Respir Res 2011; 12:114.
2. Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol 2008; 8:218-230.
3. Lotvall J, Akdis CA, Bacharier LB, et al. Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011; 127:355-360.
4. British Thoracic Society Scottish Intercollegiate Guidelines network. BTS/SIGN British Guideline on Management of Asthma. Thorax 2008; 63 (Suppl 4):iv1-iv121.
5. Kon OM, Sihra BS, Compton CH, et al. Randomised, dose-ranging, placebocontrolled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma. Lancet 1998; 352:1109-1113.
6. van den Hoogen MW, Hilbrands LB. Use of monoclonal antibodies in renal transplantation. Immunotherapy 2011; 3:871-880.
7. Busse WW, Israel E, Nelson HS, et al., Daclizumab Asthma Study Group. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: A randomized, controlled trial. Am J Respir Crit Care Med 2008; 178:1002-1008.
8. Borish LC, Nelson HS, Lanz MJ, et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999; 160:1816-1823.
9. Borish LC, Nelson HS, Corren J, et al., IL-4R Asthma Study Group. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001; 107:963-970.
10. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368:2455-2466. Elegant work showing the efficacy of Dupilumab treatment in eosinophilic asthma.
11. Hart TK, Blackburn MN, Brigham-Burke M, et al. Preclinical efficacy and safety of pascolizumab (SB240683): A humanized antiinterleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol 2002; 130:93-100.
12. Gauvreau GM, Boulet L-P, Cockcroft DW, et al. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med 2011; 183:1007-1014.
13. Kariyawasam HH, Nicholson GC, Tan AJ, et al. Effects of anti-IL-13 (Novartis QAX576) on inflammatory responses following nasal allergen challenge (NAC). Am J Respir Crit Care Med 2009; 179:A3642.
14. Singh D, Kane B, Molfino NA, et al. A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. BMC Pulm Med 2010; 10:3.
15. May R, Monk P, Cohen E, et al. Preclinical development of CAT-354, an IL-13-neutralising antibody, for the treatment of severe uncontrolled asthma. Br J Pharmacol 2012; 166:177-193.
16. Piper E, Brightling C, Niven R, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 2013; 41:330-338. A large phase II placebo-controlled study on tralokinumab in asthma evidencing the clinical effectiveness of this biologic drug.
17. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365:1088-1098.
18. Kasaian MT, Raible D, Marquette K, et al. IL-13 antibodies influence IL-13 clearance in humans by modulating scavenger activity of IL-13Ra2. J Immunol 2011; 187:561-569.
19. Burmeister Getz E, Fisher DM, Fuller R. Human pharmacokinetics/ pharmacodynamics of an interleukin-4 and interleukin-13 dual antagonist in asthma. J Clin Pharmacol 2009; 49:1025-1036.
20. Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007; 370:1422-1431.
21. Corren J, Busse W, Meltzer EO, et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010; 181:788-796.
22. Di Domenico M, Bisogno A, Polverino M, et al. Xolair in asthma therapy: An overview. Inflamm Allergy Drug Targets 2011; 10:2-12.
23. Demeule B, Shire SJ, Liu J, et al. A therapeutic antibody and its antigen form different complexes in serum than in phosphate-buffered saline: A study by analytical ultracentrifugation. Anal Biochem 2009; 388:279-287.
24. Beck LA, Marcotte GV, MacGlashan D, et al.Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol 2004; 114:527-530.
25. Schroeder JT, Bieneman AP, Chichester KL, et al. Decreases in human dendritic cell-dependent T(H)2-like responses after acute in vivo IgE neutralization. J Allergy Clin Immunol 2010; 125:896-901.
26. EMA Xolair SmPC. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/000606/WC500057298.pdf [Accessed on June 2013]
27. US Food and Drug Administration. Omalizumab (Xolair) prescribing information. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm103291.htm [Accessed on June 2013]
28. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2009. http://www.ginasthma.org
29. Domingo C, Moreno A, AmengualMJ, et al.Omalizumab in the management of oral corticosteroid-dependent IGE-mediated asthma patients. Curr Med Res Opin 2011; 27:45-53.
30. Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 2013; 131:110-116. A demonstration of effectiveness of omalizumab in nonallergic asthma, opening new horizon to the molecular activity of this humanized Ab.
31. Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007; 101:1483-1492.
32. Humbert M, Boulet LP, Niven RM, et al. Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis. Allergy 2009; 64:81-84.
33. Zaidi AK, Saini SS, MacglashanDWJr. Regulation of Syk kinase and FcRbeta expression in human basophils during treatment with omalizumab. J Allergy Clin Immunol 2010; 125:902-908.
34. Schumann C, Kropf C, Wibmer T, et al. Omalizumab in patients with severe asthma: the XCLUSIVE study. Clin Respir J 2012; 6:215-227.
35. Hochhaus G, Brookman L, Fox H, et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opinion 2003; 19:491-498.
36. Brightbill HD, Jeet S, Lin Z, et al. Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice. J Clin Invest 2010; 120:2218-2229.
37. Gauvreau G, Boulet L-P, Cockcroft DW, et al. Effect of an anti-m1 prime monoclonal antibody, Memp1972a, in a phase II proof-of-activity allergen challenge study in patients with mild asthma. Am J Resp Crit Care Med 2012; 185:A6793. First proof of concept using a strategy aimed at inhibiting switched B cells.
38. Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007; 176:1062-1071.
39. Flood-Page PT, Menzies-Gow AN, Kay AB, et al. Eosinophil's role remains uncertain as antiinterleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003; 167:199-204.
40. Leckie MJ, Ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356:2144-2148.
41. Kay AB, Menzies-Gow A. Eosinophils and interleukin-5: the debate continues. Am J Respir Crit Care Med 2003; 167:1586-1587.
42. Menzies-Gow AN, Flood-Page PT, Robinson DS, et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 2003; 111:714-719.
43. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisonedependent asthma with sputum eosinophilia. N Engl J Med 2009; 360:985-993.
44. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360:973-984.
45. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380:651-659. The first large confirmatory study of mepolizumab in eosinophilic asthma.
46. Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol 2011; 128:989-995.
47. Kips JC, O'Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized antihuman interleukin-5 antibody, in severe persistent asthma: A pilot study. Am J Respir Crit Care Med 2003; 167:1655-1659.
48. Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: A randomized, placebo controlled study. Am J Respir Crit Care Med 2011; 184:1125-1132.
49. Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol 2006; 118:1133-1141.
50. Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 2010; 125:1344-1353.
51. Busse WW, Katial R, Gossage D, et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 2010; 125:1237-1244.
52. Molfino NA, Novak R, Silverman RA, et al. Reduction in the number and severity of exacerbations following acute severe asthma: results of a placebocontrolled, randomized clinical trial with benralizumab. Am J Respir Crit Care Med 2012; 185:A2753.
53. Kay AB. The role of T lymphocytes in asthma. Chem Immunol Allergy 2006; 91:59-75.
54. Bellou A, Finn PW. Costimulation: critical pathways in the immunologic regulation of asthma. Curr Allergy Asthma Rep 2005; 5:149-154.
55. Oh CK, Geba GP, Molfino N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev 2010; 19:46-54.
56. Saggini A, Maccauro G, Tripodi D, et al. Allergic inflammation: role of cytokines with special emphasis on IL-4. Int J Immunopathol Pharmacol 2011; 24:305-311.
57. Hart P, Bonder C, Balogh J, et al. Differential responses of human monocytes and macrophages to IL-4 and IL-13. J Leukoc Biol 1999; 66:575-578.
58. Hershey GK. IL-13 receptors and signaling pathways: An evolving web. J Allergy Clin Immunol 2003; 111:677-690.
59. Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol 2008; 8:205-217.
60. Amin K. The role of mast cells in allergic inflammation. Respir Med 2012; 106:9-14.
61. Patou J, Gevaert P, Van Zele T, et al. Staphylococcus aureus enterotoxin B, protein A, and lipoteichoic acid stimulations in nasal polyps. J Allergy Clin Immunol 2008; 121:110-115.
62. Morjaria JB, Polosa R. Off-label use of omalizumab in nonasthma conditions: new opportunities. Expert Rev Resp Med 2009; 3:299-308.
63. Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol 2006; 24:147-174.
64. Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160:1001-1008.
65. Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003; 112:1029-1036.
66. Tanaka H, Komai M, Nagao K, et al. Role of interleukin-5 and eosinophils in allergen-induced airway remodeling in mice. Am J Respir Cell Mol Biol 2004; 31:62-68.
67. Molfino NA, Gossage D, Kolbeck R, et al. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin Exp Allergy 2012; 42:712-737. A comprehensive review of the rationale of targeting IL-5.
68. Hamelmann E, Oshiba A, Loader J, et al. Antiinterleukin-5 antibody prevents airway hyperresponsiveness in a murine model of airway sensitization. Am J Respir Crit Care Med 1997; 155:819-825.
69. Kung TT, Stelts DM, Zurcher JA, et al. Involvement of IL-5 in a murine model of allergic pulmonary inflammation: prophylactic and therapeutic effect of an anti-IL-5 antibody. Am J Respir Cell Mol Biol 1995; 13:360-365.
70. Mathur M, Herrmann K, Li X, et al. TRFK-5 reverses established airway eosinophilia but not established hyperresponsiveness in a murine model of chronic asthma. Am J Respir Crit Care Med 1999; 159:580-587.